ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference
ObsEva announced on March 3, 2021, that its management team will provide a corporate update during the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ObsEva announced on March 3, 2021, that its management team will provide a corporate update during the H.C. Wainwright Global Life Sciences Conference, held on March 9-10, 2021. The presentation will be available on-demand via the conference portal starting at 7 a.m. EST on March 9. ObsEva focuses on developing novel therapies to enhance women's reproductive health, with a late-stage clinical pipeline targeting endometriosis, uterine fibroids, and preterm labor. The company is publicly traded on NASDAQ under the symbol OBSV.
Details
News Market Reaction – OBSV
The recorded move for OBSV in the trading session of this news was -5.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update and participate in one-on-one investor meetings at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.
The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Tuesday, March 9, 2021.
ObsEva webcast link [here]
The presentation and archived webcast will also be accessible under “Events Calendar” in the investors section of ObsEva’s [website].
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact:
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617)-435-6602
###
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.